This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by O’Malley, B. W. Articles by Duan, L. Search for Related Content PubMed PubMed Citation Articles by O’Malley, B. W., Jr. Articles by Duan, L.

The Role of Interleukin-2 in Combination Adenovirus Gene Therapy for Head and Neck Cancer

Department of Otolaryngology — Head & Neck Surgery (B.W.O., D.A.S., D.L., L.D), Johns Hopkins University, Baltimore, Maryland 21203,
Department of Cell Biology (S.L.C.W., S.-H.C.), Baylor College of Medicine, Houston, Texas 77030,
Department of Pathology (K.-i.K.), Osaka University Medical Center, Osaka 565, Japan

Interleukin-2 (IL-2) gene therapy alone and in combination with the herpes thymidine kinase gene (tk) was used to evaluate immunological responses and antitumor effects in head and neck cancer. Established floor of mouth squamous cell carcinomas in C3H/HeJ mice were directly injected with recombinant adenoviral vectors carrying both therapeutic and control genes. One week after adenoviral gene transfer, only the animals treated with combination IL-2+tk or tk alone demonstrated significant tumor regression. Residual tumors were harvested for microscopic evaluation and immunohistochemistry staining, which revealed a predominance of CD8+ lymphocytes in the tumor beds of the animals treated with IL-2. To evaluate the systemic immune effects of IL-2, animals treated with single or combination gene therapy received a second site challenge with parental tumor cells or a heterologous but syngeneic sarcoma cell line. Mice treated with combination IL-2 and tk demonstrated a protective systemic immunity specific to the parental tumor cell line, whereas no systemic immune response was evident in mice receiving IL-2 alone. In a separate experiment, a range of concentrations of the adenovirus IL-2 vector were used to treat established tumors. Even with the maximal single-dose adenovirus concentration, IL-2 alone was ineffective as a single therapy. These results support the use of adenovirus-mediated gene transfer of IL-2 as an effective immunotherapy when used adjuvantly with the tk "suicide gene".

This article has been cited by other articles:

				K. Minemura, T. Takeda, K. Minemura, T. Nagasawa, R. Zhang, R. Leopardi, and L. J. DeGroot Cell-Specific Induction of Sensitivity to Ganciclovir in Medullary Thyroid Carcinoma Cells by Adenovirus-Mediated Gene Transfer of Herpes Simplex Virus Thymidine Kinase Endocrinology, May 1, 2000; 141(5): 1814 - 1822. [Abstract] [Full Text] [PDF]

				D. Li, W. Jiang, J. S. Bishop, R. Ralston, and B. W. O'Malley Jr. Combination Surgery and Nonviral Interleukin 2 Gene Therapy for Head and Neck Cancer Clin. Cancer Res., June 1, 1999; 5(6): 1551 - 1556. [Abstract] [Full Text] [PDF]

				R. Zhang, F. H. Straus, and L. J. DeGroot Effective Genetic Therapy of Established Medullary Thyroid Carcinomas with Murine Interleukin-2: Dissemination and Cytotoxicity Studies in a Rat Tumor Model Endocrinology, May 1, 1999; 140(5): 2152 - 2158. [Abstract] [Full Text]

				X. Danthinne, K. Aoki, A. L. Kurachi, G. J. Nabel, and E. G. Nabel Combination Gene Delivery of the Cell Cycle Inhibitor p27 with Thymidine Kinase Enhances Prodrug Cytotoxicity J. Virol., November 1, 1998; 72(11): 9201 - 9207. [Abstract] [Full Text] [PDF]

				R. Zhang, K. Minemura, and L. J. De Groot Immunotherapy for Medullary Thyroid Carcinoma by a Replication-Defective Adenovirus Transducing Murine Interleukin-2 Endocrinology, February 1, 1998; 139(2): 601 - 608. [Abstract] [Full Text] [PDF]